ArticleFrontiers in immunology2026
ANXA2 promotes NLRP3 inflammasome activation and neuronal pyroptosis after intracerebral hemorrhage.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intracerebral hemorrhage (ICH) is a severe form of stroke lacking effective pharmacotherapy, in part because upstream regulators initiating secondary brain injury are not well understood. Pyroptosis mediated by activation of the NLRP3 inflammasome is a major contributor to neuronal death after ICH. However, the upstream mechanisms remain to be fully elucidated. Methods: We performed integrative transcriptomic-proteomic profiling of mouse ICH brain tissues with Results: Multi-omics and network analyses identified ANXA2 as a prominently upregulated hub protein after ICH. Co-immunoprecipitation demonstrated an association between ANXA2 and NLRP3, while ANXA2 silencing reduced NLRP3 inflammasome activation, decreased GSDMD cleavage and IL-1β/IL-18 secretion and significantly improved neurological function while alleviating brain injury. Conclusions: This study reveals a previously unrecognized ANXA2-NLRP3-pyroptosis pathway in ICH, revealing a neuronal-immune convergence mechanism in inflammasome regulation. These findings provide new insight into neuronal pyroptosis after ICH and underscore ANXA2 as a predominantly neuronal factor associated with inflammasome activation in hemorrhagic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.